key: cord-0686481-n3a89jxv
authors: Velarde-Ruiz Velasco, J. A.; García-Jiménez, E. S.; Remes-Troche, J. M.
title: Hepatic manifestations and impact of COVID-19 on the cirrhotic patient
date: 2020-07-09
journal: nan
DOI: 10.1016/j.rgmxen.2020.05.002
sha: c40345a9ce5a47568c234b43f5ccd422ea8f975d
doc_id: 686481
cord_uid: n3a89jxv

Abstract The novel SARS-CoV-2 coronavirus is responsible for the infectious disease caused by coronavirus 19 (COVID-19). The current pandemic is growing worldwide and could affect 50-60% of the world population in the months to come. The most severe disease manifestations are atypical pneumonia and sepsis, but the gastrointestinal tract, particularly the liver, has recently been reported to be affected by SARS-CoV-2. Therefore, the aim of the present work was to review the literature available on the topic and provide information about COVID-19, in both healthy and diseased livers, and issue recommendations. The incidence of liver injury specifically associated with COVID-19 varies from 14.8-53%. The majority of case series have reported altered ALT and AST, elevated total bilirubin, and low serum albumin and liver compromise has been associated with the most severe cases of COVID-19. Cirrhosis of the liver has a recognized immune dysfunction status that includes immunodeficiency and systemic inflammation, making it reasonable for those patients to be more susceptible to SARS-CoV-2 infection. The recommendations for those patients, in addition to the general measures of physical distancing and handwashing for all persons, include social, medical, and psychologic support during the period of home quarantine to prevent lapses in treatment. Patients should be made aware that they need to keep abreast of changes in recommendations and social policies.

Coronaviruses are enveloped, positive-sense RNA viruses that vary from 60 nm to 140 nm in diameter, with projections in the form of spikes that give the appearance of a crown, hence the name. Up to November 2019 there were four known coronaviruses that presented in humans, causing mild respiratory infections: HKU1, NL63, 229E, and OC43. [1] [2] The appearance of a new human coronavirus has recently been described, first reported in the city of Wuhan, China. The novel coronavirus, SARS-CoV-2, is a beta coronavirus, of the subgenus Sarbecovirus and the subfamily Orthocoronavirinae. The organization of the viral genome of the Wuhan Human-1 coronavirus was determined through the sequencing alignment of two beta coronaviruses: one associated with humans (SARS-CoV Tor2) and one associated with bats (bat SL-CoVZC45). [3] [4] The infectious disease due to coronavirus , so-named by the World Health Organization (WHO) on February 11, 2020, is caused by the SARS-CoV-2 virus and is the causal agent of a potentially fatal disease that has become a huge public health problem across the globe. 5 By February 24, 2020, more than 80,000 confirmed cases were registered worldwide, in at least 37 countries, and more than 2,700 deaths, resulting in a worldwide health emergency declared by the WHO. 6 In Mexico, the first case was reported on February 27 and two days later four cases were confirmed by the Mexican Health Department. All cases were traced back to an individual from Bergamo, Italy. 7 The progression of this pandemic is rising worldwide, and 3,525,116 confirmed cases were reported by May 5, 8 with a mortality rate of 3.4%. In Mexico, by that same date, there were 24,905 confirmed J o u r n a l P r e -p r o o f cases and 2,271 deaths due to COVID-19. 9 Even though it is a disease whose most severe manifestations are atypical pneumonia and sepsis, the digestive tract, particularly the liver, has recently been reported to be affected by SARS-CoV-2. [10] [11] Therefore, the aim of the present work was to review the available literature on the topic and provide recommendations related to the role of COVID-19 in both healthy and diseased livers. Platform (ICTRP). The search was carried out within the time frame of January 1, 2020 to April 10, 2020, utilizing the search term "coronavirus" combined with the following terms: "SARS-CoV-2", "liver", "hepatic", "enzymes", "acute" "chronic", "cirrhosis", "liver failure", "hepatitis", "COVID-19" and their Spanish equivalents. We found 98 works and included 47 in the present review. The excluded articles were case reports, duplicate publications, or those in a language other than Spanish or English.

J o u r n a l P r e -p r o o f

The clinical manifestations of COVID-19 are varied and range from an asymptomatic state to the more severe acute respiratory distress syndrome (ARDS) and multiorgan dysfunction. The common signs and symptoms are fever, cough, sore throat, headache, fatigue, myalgia, dyspnea, and conjunctivitis, but can progress to pneumonia, respiratory failure, and death. 1 In addition, patients with COVID-19 infection have also presented with gastrointestinal symptoms, such as diarrhea, and a low percentage of patients with MERS-CoV or SARS-CoV present with similar gastrointestinal complaints. Symptoms appear after an incubation period of approximately 5.2 days. 5 A metalloproteinase called angiotensin-converting enzyme 2 (ACE2) has been identified as the functional receptor for coronavirus cell entry. ACE2 microRNA expression has been found in multiple organs and human tissue, including the oral and nasal mucosa, nasopharynx, lung, stomach, small bowel, colon, skin, lymph nodes, thymus, bone marrow, spleen, kidney, brain, biliary epithelium, and liver, making its expression a potential target for infection. 1, [12] [13] [14] [15] Thus, the liver is an organ that is affected by COVID-19. There is information that the liver, either healthy or presenting with a pre-existing hepatic disease, is a pathophysiologic target for that family of coronaviruses. Liver injury (hepatitis) in patients with SARS is manifested through mild-to-moderate elevation of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) during the early disease stage, as well as a decrease in serum albumin and an increase in serum bilirubin levels. Autopsy findings in patients with SARS show a large number of J o u r n a l P r e -p r o o f viral particles, not only in the lungs, but also in parenchymal cells and the vascular endothelium of other organs, including the liver. 12 The incidence of liver injury specifically associated with COVID-19 varies from 14.8-53%. The majority of case series have reported alterations in ALT and AST, elevated total bilirubin, and low serum albumin. 12 Chen et al. reported a case series of 99 cases of pneumonia due to COVID-19, in which only one patient had a lesion with a severe hepatocellular pattern and elevated ALT and AST, whereas the rest of the patients had moderately elevated aminotransferase levels. A decrease in albumin was present in the majority of the cases. With respect to the coagulation profile, the prothrombin time increased in only 5% of the cases, highlighting an increase in dimer levels in one-third of the patients ( fig. 1 ). 16 Likewise, Huang et al. found similar liver biochemistry alterations, describing elevated AST levels in 37% of the patients, with a higher number of those cases in the patients that were admitted to the intensive care unit (ICU) (62% vs. 25%). 17 In a case series of 138 COVID-19 cases, Wang et al. also found statistically higher AST levels in patients that required ICU admission (p < 0.001). 18 In addition, there are studies in which the presence of liver alterations has been related to death. In their case series on mortality from SARS-CoV-2 in 82 cases, Zhang et al. reported that the median of time from symptom onset until death was 15 days. With respect to transaminase elevation, there was a significant association between AST (p = 0.002), ALT (p = 0.037), and the time from symptom onset until death. 19 In another report, Huang et al. described the clinical characteristics of 36 patients that did not survive COVID-19. The liver chemistry alterations behaved similarly to those in previous reports, with elevated ALT in 13.3%, elevated AST in 58%, a decrease in albumin in 80%, an increase in total bilirubin in 13%, and an increase in D dimer in 100% of the cases. 20 Finally, Zhou et al. reported that in 191 patients with COVID-19, 31% presented with an elevation of ALT > 40 U/L. In the subgroup of patients that died, ALT was elevated in 48% of the cases, vs. 24% of the patients in the group that survived (p = 0.0050). 21 In that context, the report on 1,099 patients with COVID-19, conducted by Guang et al., stated that AST elevation was > 40 U/L in 39% of the patients and that ALT elevation was > 40 U/L in 28% of the patients with severe disease.

Of the patients that required ICU admission, mechanical ventilation, or that died, 50% had elevated AST and 28% had elevated ALT. 22 Table 1 summarizes the characteristics of liver chemistry alterations and their outcomes.

Due to the problem of access to biopsy or autopsy reports, the histopathologic findings of this new disease are not yet completely defined. A case report by Xu et al. 23 presented the post-mortem biopsy results of a 50-year-old man who died from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). With respect to the liver biopsies, there was microvesicular steatosis and mild lobular and portal inflammatory activity. Nevertheless, it was not completely certain if the liver injury was due to SARS-CoV-2 or to drug-induced liver injury (DILI). The latter diagnostic probability is sustained by the fact that numerous drugs with great hepatotoxic potential, such as remdesivir, tocilizumab, chloroquine, and statins, are empirically used in some cases to treat severe SARS-CoV-2, all of which can make the J o u r n a l P r e -p r o o f coronavirus patient prone to developing DILI. 12 There was also no information in the case report about any comorbidities, to know if the patient could have been at risk due to a pre-existing liver disease. All of this leads to the hypothesis that elevated aminotransferases may be the result of a direct effect on the hepatocyte mediated by the virus, or of a liver injury mediated by immune and inflammatory activation associated with the infection. 

Patients with cirrhosis of the liver (CL) are immunocompromised and more susceptible to developing spontaneous bacterial infections, some of which are due to uncommon pathogens, reflected in a higher mortality rate close to 30%. 26 Patients with CL, especially in the decompensated stage, are susceptible to the development of those infections, whose prevalence can increase to 44%. 27 Thus, CL is a state of immune dysfunction that encompasses immunodeficiency and systemic inflammation, exhibiting at least two known phenotypes of immune dysfunction in cirrhosis: the proinflammatory and the immunodeficient. They are characterized by the differences in cytokine activity, phagocyte activity, and HLA expression, among others, that present throughout the pathophysiologic stages from compensated stages to decompensated stages, and up to acute-on-chronic liver failure (ACLF). 28 Said immunodeficiency also results in a reduced synthesis of pattern recognition receptors (PRRs). 29 Different classes of germline-encoded PRRs recognize invasive pathogens and monitor the extracellular and intracellular compartments of host cells to detect signs of invasion by microorganisms. 30 The liver is the primary source of PRRs (e.g., C-reactive protein, lipopolysaccharide 

Throughout history, there have been outbreaks and epidemics of viral diseases, especially respiratory diseases. The most recent is the COVID-19 pandemic.

Patients with chronic liver disease (CLD) present with multifactorial immune dysfunction. [33] [34] Due to the fact that the infection site affects outcome in patients with CLD, acute respiratory diseases acquire great importance because they produce an almost 40-fold increase in the hospitalization rate, compared with the general population. 34 They also generate a 2.95-fold increase in 30-day mortality in the community setting and up to an 11-fold increase in the hospital setting, the highest among isolated infectious complications. 33 The prevalence of pneumonia and influenza reported in 2009 in the United States was 0.38% and 0.027%, respectively. 34 As expected, patients with a higher grade of decompensation have a higher mortality rate in those types of events and associated factors are inadequate antibiotic use, bacteremia, leukocyte count, total bilirubin, more J o u r n a l P r e -p r o o f advanced age, and alcoholic disease etiology, as well as the development of organ failure and ACLF. 33 Models developed during community outbreaks of influenzalike disease indicate an increase in morbidity and mortality in patients with CLD, mainly related to organ failure and complications associated with liver disease, such as gastrointestinal bleeding. 35 Patients with CLD are prone to developing respiratory failure due to numerous causes. They can also present with disease modifiers that worsen its natural history, such as smoking, chronic obstructive pulmonary disease, malnutrition, muscle deconditioning and wasting, hypoalbuminemia, coagulopathy, multiple transfusions, etc. In addition, ascites directly affects pulmonary and respiratory mechanics by increasing the intra-abdominal pressure, and hepatic encephalopathy increases the risk for micro-aspirations and ineffective cough. 36 Thus, up to 70% of patients with CLD can present with arterial hypoxemia. An assisted ventilation event in patients with cirrhosis, especially in the context of ARDS, has a mortality rate of 59% to 100% in nontransplant hospitals. 36 The mortality rate in patients with CLD in ICUs is 46-90%. In the context of ARDS, that outcome appears to be associated more with the development of extrapulmonary The accumulated mortality rate after any infection in patients with cirrhosis is 43.5%, whereas the mortality rate with no infection is only 13.6%. 39 Furthermore, short-term and long-term outcomes that occur after an acute respiratory failure event must be added, especially if mechanical ventilation is required, and they are generally worse than outcomes in cirrhotic patients without those conditions. 40

The first epidemiologic reports characterizing patients with COVID-19 came out of China. One of those reports provided data from 1,099 patients, 23 of whom had chronic hepatitis B virus (HBV) infection. 22 The probability of having presented with HBV was greater in the patients with severe COVID-19 disease than in the nonsevere cases. 41 In another report from Wuhan, China, on a total of 138 patients, four of them presented with CLD but did not require ICU admission. The most current experience at the Renmin Hospital of the University of Wuhan in patients with decompensated liver cirrhosis provided data on 111 patients. Their mean age was 58.7 years, 82 were outpatients, and 29 were inpatients. 42 In the most recent report from Lombardy, Italy, on 1,591 critically ill patients, 3% of them had CLD. 43 and psychologic support are of vast importance to prevent both treatment interruption and the relapse into alcohol consumption by patients with alcoholrelated CLD. Patients must be made aware that they have to keep abreast of changes in the recommendations and social policies and be instructed not to take substances or medications that have not been prescribed by their physician, including supplements or alternative products, as measures of "prevention" or to "strengthen the immune system" etc. How long the pandemic will last is not known, therefore an essential recommendation is that the influenza vaccination regimen in patients with CLD be up to date.

The standard of medical care for patients that are hospitalized due to causes other than COVID-19 remains the same, with certain recommendations as to the selection of emergency or elective procedures, outlined in table 2. Likewise, despite the fact that there is no standardized treatment for COVID-19 management in patients with severe disease, the indications for liver health summarized in table   3 should be taken into account.

According to the information reported in the international medical literature, hepatic manifestations of SARS-CoV-2 are common and the more severe alterations are J o u r n a l P r e -p r o o f associated with poor outcome. Severe cases are beginning to present in Mexico, underlining the importance of being aware of hepatic manifestations in the general population, so that cases potentially requiring opportune hospitalization can be recognized. On the other hand, COVID-19 infection in patients with pre-existing CLD implies a greater risk and probability of liver dysfunction, and so healthcare professionals in charge of those patients are recommended to be alert regarding the development of potential complications. There may be questions as to the usefulness of the strategies proposed herein, but when dealing with an emerging pathology of the current magnitude it is impossible to provide recommendations that have been proven 100%. The disease, its behavior, and the data reported over the past few months have been dynamic, and thus should not be considered definitive or unalterable. For the benefit of our patients with cirrhosis of the liver, we must continuously be updating our information. It is also important to recognize that more studies on different populations are needed to have a complete understanding of the morbidity and mortality associated with SARS-CoV-2 in the cirrhotic patient. 

A Review of Coronavirus Disease-2019 (COVID-19)

A Genomic Perspective on the Origin and Emergence of SARS-CoV-2

The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak -an update on the status

A new coronavirus associated with human respiratory disease in China

The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak

SARS-CoV-2 and COVID-19: The most important research questions

Conferencias de prensa Fase 1 29 febrero

COVID-19)-Comunicado ténico diario. Dirección General de Epidemiología

AGA Institute Rapid Review of the GI and Liver Manifestations of COVID-19, Meta-Analysis of International Data, and J o u r n a l P r e -p r o o f Recommendations for the Consultative Management of Patients with COVID-19. AGA. 2020

Covid-19 and the digestive system

Liver injury during highly pathogenic human coronavirus infections

Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis

The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak -an update on the status

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China

Clinical characteristics of 82 death cases with COVID-19. medRxiv

Clinical characteristics of 36 non-survivors with COVID-19 in Wuhan

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Clinical Characteristics of Coronavirus Disease 2019 in China

Pathological findings of COVID-19 associated with acute respiratory distress syndrome

Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past

COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up

Bacterial infections, sepsis, and multiorgan failure in cirrhosis

Bacterial infection in patients with advanced cirrhosis: a multicentre prospective study

Cirrhosis-associated immune dysfunction: distinctive features and clinical relevance

Liver: an organ with predominant innate immunity

Immune dysfunction in cirrhosis

The liver as a lymphoid organ

Hepatocytes: a key cell type for innate immunity

Pneumonia in patients with cirrhosis: risk factors associated with mortality and predictive value of prognostic models

Higher mortality and hospital charges in patients with cirrhosis and acute respiratory illness: a population-based study

Clinical impact of A/H1/N1/09 influenza in patients with cirrhosis: experience from a nosocomial cluster of infection

Acute respiratory failure complicating advanced liver disease

Implications of COVID-19 for patients with pre-existing digestive diseases

Prevention of SARS-CoV-2 infection in patients with decompensated cirrhosis

Baseline Characteristics and Outcomes of 1591

Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region

Surveillance Epidemiology of Coronavirus (COVID-19) Under Research Exclusion. SECURE-Cirrhosis Registry

COVID 19 in patients with liver disease or transplantation. COVID-HEP Registry

Preliminary Estimates of the Prevalence of Selected Underlying Health Conditions Among Patients with Coronavirus Disease 2019 -United States

Report on COVID-19 in critical care

J o u r n a l P r e -p r o o f Chen, et al. 16 Se adjunta Figura 2 en versión editable Power Point. J o u r n a l P r e -p r o o f x Carry out the rest of the approach to decompensation High-volume paracentesis (asymptomatic/responder to diuretics)xOptimize diuretic dose, monitoring kidney function and weightHigh-volume paracentesis (untreatable/respiratory restriction or other symptoms)x Distancing measures, mask use, handwashing, no touching of surfaces whenever possible, perform in a nonhospital setting Thoracentesis (hepatic hydrothorax)x Distancing measures, mask use, handwashing, no touching of surfaces whenever possible, perform in a nonhospital setting TIPSx Optimize drug management J o u r n a l P r e -p r o o f 

Minimally metabolized in the liver, its mechanism of injury is unknown but thought to be related to its effects on the immune system or the IL-6 pathway (important in liver regeneration). SarilumabAminotransferase elevation 4-5 times more frequent than with placebo in clinical trials (4-5% of patients). Mild bilirubin elevation. No reports of clinically apparent liver injury in self-limited episodes. It is suspected to predispose to reactivation of hepatitis. Minimally metabolized in the liver, its mechanism of injury is unknown, but it is thought to be related to its effect on the immune system or the IL-6 pathway.